These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6844367)

  • 1. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice.
    Vallé-Jones JC; Brodie NH; O'Hara H; O'Hara J; McGhie RL
    Pharmatherapeutica; 1983; 3(5):300-4. PubMed ID: 6844367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.
    Hendricks EJ; Greenway FL; Westman EC; Gupta AK
    Obesity (Silver Spring); 2011 Dec; 19(12):2351-60. PubMed ID: 21527891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double blind evaluation of long acting diethylpropion hydrochloride in obese patients from a general practice.
    Carney DE; Tweddell ED
    Med J Aust; 1975 Jan; 1(1):13-5. PubMed ID: 1092973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind controlled study of the use of diethylpropion hydrochloride (Tenuate) in obese patients in a rural practice.
    Elliott BJ
    N Z Med J; 1978 Oct; 88(622):321-2. PubMed ID: 282482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diethylpropion in the treatment of obese patients seen in general practice.
    Matthews PA
    Curr Ther Res Clin Exp; 1975 Apr; 17(4):340-6. PubMed ID: 804381
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release diethylpropion hydrochloride used in a program for weight reduction.
    Parsons WB
    Clin Ther; 1981; 3(5):329-35. PubMed ID: 7471128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of obesity. The initial and continued effectiveness of tenuate in intermittent therapy of moderately and severely obese patients. Double-blind study].
    Albach E; Gianoli AC
    Fortschr Med; 1977 Sep; 95(33):2040-4. PubMed ID: 334650
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients.
    Follows OJ
    Br J Clin Pract; 1971 May; 25(5):236-8. PubMed ID: 4931755
    [No Abstract]   [Full Text] [Related]  

  • 10. Femoxetine in the treatment of obese patients in general practice. A randomized group comparative study with placebo.
    Bitsch M; Skrumsager BK
    Int J Obes; 1987; 11(2):183-90. PubMed ID: 3301710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat.
    Limón-Bernal E; Roa-Coria JE; Zúñiga-Romero Á; Huerta-Cruz JC; Ruíz-Velasco IRC; Flores-Murrieta FJ; Lara-Padilla E; Reyes-García JG; Rocha-González HI
    Behav Pharmacol; 2021 Aug; 32(5):368-381. PubMed ID: 33660661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight loss medications--where do they fit in?
    Dixon JB
    Aust Fam Physician; 2006 Aug; 35(8):576-9. PubMed ID: 16894428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status of antiobesity drugs.
    Galloway SM; Farquhar DL; Munro JF
    Postgrad Med J; 1984; 60 Suppl 3():19-26. PubMed ID: 6393107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diethylpropion hydrochloride (Tenuate Dospan) in combination with hypotensive agents in the treatment of obesity associated with hypertension.
    Seedat YK; Reddy J
    Curr Ther Res Clin Exp; 1974 May; 16(5):398-413. PubMed ID: 4209056
    [No Abstract]   [Full Text] [Related]  

  • 18. Diet pill psychosis.
    Hoffman BF
    Can Med Assoc J; 1977 Feb; 116(4):351-5. PubMed ID: 844014
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.
    Murphy JE; Donald JF; Molla AL; Crowder D
    J Int Med Res; 1975; 3(3):202-6. PubMed ID: 162676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of behavioral techniques reinforced with an anorectic drug in a double-blind weight loss study.
    Abramson R; Garg M; Cioffari A; Rotman PA
    J Clin Psychiatry; 1980 Jul; 41(7):234-7. PubMed ID: 6993445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.